CVR Energy (CVI) Declares Special Dividend of $6.50

CVR Energy (NYSE:CVI) announced a special dividend on Tuesday, May 28th, AnalystRatings.Net reports. Stockholders of record on Monday, June 3rd will be paid a dividend of $6.50 per share on Monday, June 10th.

CVI has been the subject of a number of recent research reports. Analysts at Macquarie upgraded shares of CVR Energy from an “underperform” rating to a “neutral” rating in a research note to investors on Wednesday, May 22nd. They now have a $71.00 price target on the stock, up previously from $50.00. On the ratings front, analysts at Deutsche Bank cut their price target on shares of CVR Energy from $60.00 to $50.00 in a research note to investors on Wednesday, April 17th. They now have a “hold” rating on the stock.

Shares of CVR Energy (NYSE: CVI) opened at 69.73 on Tuesday. CVR Energy has a 52 week low of $23.54 and a 52 week high of $69.51. The stock’s 50-day moving average is currently $54.6. The company has a market cap of $6.055 billion and a P/E ratio of 10.44.

CVR Energy (NYSE: CVI) last released its earnings data on Wednesday, May 1st. The company reported $1.90 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.48 by $0.42. The company had revenue of $2.35 billion for the quarter, compared to the consensus estimate of $2.19 billion. During the same quarter last year, the company posted $0.76 earnings per share. CVR Energy’s revenue was up 19.5% compared to the same quarter last year. Analysts expect that CVR Energy will post $5.91 EPS for the current fiscal year.

CVR Energy, Inc. (NYSE: CVI) is an independent petroleum refiner and marketer of transportation fuels.

Latest News

Superior Energy Services  Lowered to “Market Perform” at Raymond James
Superior Energy Services Lowered to “Market Perform” at Raymond James
The Ultimate Software Group  Rating Increased to Outperform at Evercore ISI
The Ultimate Software Group Rating Increased to Outperform at Evercore ISI
Avalara  Upgraded to “Overweight” at JPMorgan Chase & Co.
Avalara Upgraded to “Overweight” at JPMorgan Chase & Co.
Novavax, Inc.  Expected to Earn Q4 2018 Earnings of  Per Share
Novavax, Inc. Expected to Earn Q4 2018 Earnings of Per Share
The Medicines  Now Covered by Analysts at Goldman Sachs Group
The Medicines Now Covered by Analysts at Goldman Sachs Group
Aimmune Therapeutics  Given a $64.00 Price Target by Cantor Fitzgerald Analysts
Aimmune Therapeutics Given a $64.00 Price Target by Cantor Fitzgerald Analysts


© 2006-2018 Ticker Report